Search Results

You are looking at 11 - 20 of 22 items for :

  • SGLT2 inhibitors x
Clear All
Paraskevi Kazakou Diabetes Centre, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Paraskevi Kazakou in
Google Scholar
PubMed
Close
,
Stavroula A Paschou Endocrine Unit, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Stavroula A Paschou in
Google Scholar
PubMed
Close
,
Theodora Psaltopoulou Unit of Hematology and Oncology, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Theodora Psaltopoulou in
Google Scholar
PubMed
Close
,
Maria Gavriatopoulou Unit of Hematology and Oncology, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Maria Gavriatopoulou in
Google Scholar
PubMed
Close
,
Eleni Korompoki Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Eleni Korompoki in
Google Scholar
PubMed
Close
,
Katerina Stefanaki Endocrine Unit, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Katerina Stefanaki in
Google Scholar
PubMed
Close
,
Fotini Kanouta Department of Endocrinology, Alexandra Hospital, Athens, Greece

Search for other papers by Fotini Kanouta in
Google Scholar
PubMed
Close
,
Georgia N Kassi Department of Endocrinology, Alexandra Hospital, Athens, Greece

Search for other papers by Georgia N Kassi in
Google Scholar
PubMed
Close
,
Meletios-Athanasios Dimopoulos Unit of Hematology and Oncology, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Meletios-Athanasios Dimopoulos in
Google Scholar
PubMed
Close
, and
Asimina Mitrakou Diabetes Centre, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Asimina Mitrakou in
Google Scholar
PubMed
Close

, irrespective of preexisting glycemic status, disease severity, or glucocorticoid use ( 49 , 50 ). Of note, several case series of euglycaemic DKA in patients with T2DM and COVID-19 while on sodium-glucose cotransporter-2 inhibitors (SGLT2is) have been

Open access
Hui-qing Yuan Department of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong City, Nantong, China

Search for other papers by Hui-qing Yuan in
Google Scholar
PubMed
Close
,
Jia-xi Miao Department of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong City, Nantong, China

Search for other papers by Jia-xi Miao in
Google Scholar
PubMed
Close
,
Jia-ping Xu Department of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong City, Nantong, China

Search for other papers by Jia-ping Xu in
Google Scholar
PubMed
Close
,
Su-xiang Zhu Department of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong City, Nantong, China

Search for other papers by Su-xiang Zhu in
Google Scholar
PubMed
Close
,
Feng Xu Department of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong City, Nantong, China

Search for other papers by Feng Xu in
Google Scholar
PubMed
Close
,
Xiao-hua Wang Department of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong City, Nantong, China

Search for other papers by Xiao-hua Wang in
Google Scholar
PubMed
Close
,
Chun-hua Wang Department of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong City, Nantong, China

Search for other papers by Chun-hua Wang in
Google Scholar
PubMed
Close
,
Chao Yu Department of Clinical Laboratory, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong City, Nantong, China

Search for other papers by Chao Yu in
Google Scholar
PubMed
Close
,
Xue-qin Wang Department of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong City, Nantong, China

Search for other papers by Xue-qin Wang in
Google Scholar
PubMed
Close
,
Jian-bin Su Department of Endocrinology, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong City, Nantong, China

Search for other papers by Jian-bin Su in
Google Scholar
PubMed
Close
, and
Dong-mei Zhang Medical Research Center, Affiliated Hospital 2 of Nantong University, and First People’s Hospital of Nantong City, Nantong, China

Search for other papers by Dong-mei Zhang in
Google Scholar
PubMed
Close

glucose cotransporter 2 inhibitors (SGLT-2Is); (x) connective tissue diseases. At last, complete data from 2634 eligible patients were qualified for this cross-sectional study. The study conduction was adhered to the Declaration of Helsinki involving

Open access
Run-Qing Xiong Department of Ultrasonic Imaging, Xiamen Medical College Affiliated Second Hospital, Fujian, China

Search for other papers by Run-Qing Xiong in
Google Scholar
PubMed
Close
,
Yan-Ping Li Key Laboratory of Functional and Clinical Translational Medicine, Fujian Province University, Xiamen Medical College, Fujian, China

Search for other papers by Yan-Ping Li in
Google Scholar
PubMed
Close
,
Lu-Ping Lin Department of Endocrinology, Xiamen Medical College Affiliated Second Hospital, Fujian, China

Search for other papers by Lu-Ping Lin in
Google Scholar
PubMed
Close
, and
Jeng-Yuan Yao Key Laboratory of Functional and Clinical Translational Medicine, Fujian Province University, Xiamen Medical College, Fujian, China

Search for other papers by Jeng-Yuan Yao in
Google Scholar
PubMed
Close

potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy . Frontiers in Cardiovascular Medicine 2022 9 999254 . ( https://doi.org/10.3389/fcvm.2022.999254 ) 21 Peng M Xia T Zhong Y Zhao M Yue Y Liang L Zhong

Open access
Iben Rix Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Zealand Pharma A/S, Søborg, Denmark

Search for other papers by Iben Rix in
Google Scholar
PubMed
Close
,
Marie L Johansen Department of Medicine, Herlev Hospital, University of Copenhagen, Herlev, Denmark

Search for other papers by Marie L Johansen in
Google Scholar
PubMed
Close
,
Asger Lund Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

Search for other papers by Asger Lund in
Google Scholar
PubMed
Close
,
Malte P Suppli Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark

Search for other papers by Malte P Suppli in
Google Scholar
PubMed
Close
,
Elizaveta Chabanova Department of Radiology, Herlev Hospital, University of Copenhagen, Herlev, Denmark

Search for other papers by Elizaveta Chabanova in
Google Scholar
PubMed
Close
,
Gerrit van Hall Clinical Metabolomics Core Facility, Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Gerrit van Hall in
Google Scholar
PubMed
Close
,
Jens J Holst Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Jens J Holst in
Google Scholar
PubMed
Close
,
Nicolai J Wewer Albrechtsen Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Nicolai J Wewer Albrechtsen in
Google Scholar
PubMed
Close
,
Caroline Kistorp Department of Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Caroline Kistorp in
Google Scholar
PubMed
Close
, and
Filip K Knop Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Steno Diabetes Center Copenhagen, Herlev, Denmark

Search for other papers by Filip K Knop in
Google Scholar
PubMed
Close

(2597–3021) 0.91 Diabetes medication, n (%)  Metformin 91 (82.7%) 46 (79.3%) 45 (86.5%) 0.32  SGLT-2 inhibitor 18 (16.4%) 7 (12.1%) 11 (21.2%) 0.20  Sulphonylurea 11 (10.0%) 4 (6.9%) 7 (13.5%) 0

Open access
David Koeckerling Medical Sciences Division, University of Oxford, Oxford, UK

Search for other papers by David Koeckerling in
Google Scholar
PubMed
Close
,
Jeremy W Tomlinson Oxford Centre for Diabetes, Endocrinology & Metabolism, University of Oxford, Oxford, UK

Search for other papers by Jeremy W Tomlinson in
Google Scholar
PubMed
Close
, and
Jeremy F Cobbold Oxford Liver Unit, NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK

Search for other papers by Jeremy F Cobbold in
Google Scholar
PubMed
Close

reduction and cardiovascular event incidence ( 91 , 92 ). The safety and efficacy of semaglutide in NAFLD is being investigated in phase II clinical trials. Sodium-glucose transport protein-2 (SGLT-2) inhibitors impede renal glucose reabsorption, serving

Open access
Qian Deng Graduate College of Anhui University of Chinese Medicine, Hefei, China

Search for other papers by Qian Deng in
Google Scholar
PubMed
Close
,
Yue Zhu Graduate College of Anhui University of Chinese Medicine, Hefei, China

Search for other papers by Yue Zhu in
Google Scholar
PubMed
Close
,
Mengmeng Zhang Graduate College of Anhui University of Chinese Medicine, Hefei, China

Search for other papers by Mengmeng Zhang in
Google Scholar
PubMed
Close
,
Aihua Fei Department of Endocrinology, The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China

Search for other papers by Aihua Fei in
Google Scholar
PubMed
Close
,
Jiaqi Liang Graduate College of Anhui University of Chinese Medicine, Hefei, China

Search for other papers by Jiaqi Liang in
Google Scholar
PubMed
Close
,
Jinjin Zheng Graduate College of Anhui University of Chinese Medicine, Hefei, China

Search for other papers by Jinjin Zheng in
Google Scholar
PubMed
Close
,
Qingping Zhang College of Acupuncture-moxibustion and Tuina, Anhui University of Chinese Medicine, Hefei, China

Search for other papers by Qingping Zhang in
Google Scholar
PubMed
Close
,
Tong Cheng Department of Geriatrics, Zhongshan Hospital, Fudan University, Shanghai, China

Search for other papers by Tong Cheng in
Google Scholar
PubMed
Close
, and
Xia Ge Department of Endocrinology, The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China

Search for other papers by Xia Ge in
Google Scholar
PubMed
Close

diabetes-related ferroptosis, thus delaying the progression of DN ( 108 , 109 , 110 ). Canagliflozin (Cana) is a new sodium-glucose cotransporter 2 inhibitor (SGLT2i) hypoglycemic drug; it can improve diabetic myocardial structure and function, preserve

Open access
Aldo Bonaventura Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Search for other papers by Aldo Bonaventura in
Google Scholar
PubMed
Close
,
Fabrizio Montecucco Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Search for other papers by Fabrizio Montecucco in
Google Scholar
PubMed
Close
, and
Franco Dallegri Department of Internal Medicine, Division of Cardiology, Division of Laboratory Medicine, First Clinic of Internal Medicine, University of Genoa School of Medicine, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Search for other papers by Franco Dallegri in
Google Scholar
PubMed
Close

hypoglycemia (31% lower) (76) . The frequency of hypoglycemia with new GLDs, such as incretins and SGLT2 inhibitors, is very low (77) . Results of some trials indicated the efficacy of dipeptidyl peptidase (DPP)-4 inhibitors in improving glycemic control

Open access
Wenrui Wang Department of Endocrinology, The Second Hospital of Jilin University, Changchun, People’s Republic of China

Search for other papers by Wenrui Wang in
Google Scholar
PubMed
Close
and
Chuan Zhang Department of Endocrinology, The Second Hospital of Jilin University, Changchun, People’s Republic of China

Search for other papers by Chuan Zhang in
Google Scholar
PubMed
Close

antidiabetic drugs include metformin, thiazolidinediones, α-glucosidase inhibitors, insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter type 2 inhibitors (SGLT2is); which may enhance

Open access
Xiaoxia Jia Center for Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China

Search for other papers by Xiaoxia Jia in
Google Scholar
PubMed
Close
,
Yaxin An Center for Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China

Search for other papers by Yaxin An in
Google Scholar
PubMed
Close
,
Yuechao Xu Center for Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China

Search for other papers by Yuechao Xu in
Google Scholar
PubMed
Close
,
Yuxian Yang Center for Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China

Search for other papers by Yuxian Yang in
Google Scholar
PubMed
Close
,
Chang Liu Center for Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China

Search for other papers by Chang Liu in
Google Scholar
PubMed
Close
,
Dong Zhao Center for Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China

Search for other papers by Dong Zhao in
Google Scholar
PubMed
Close
, and
Jing Ke Center for Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China
Beijing Key Laboratory of Diabetes Research and Care, Beijing, China

Search for other papers by Jing Ke in
Google Scholar
PubMed
Close

2015 100 274 – 281 . ( https://doi.org/10.1210/jc.2014-2583 ) 30 Zhao Y Gao P Sun F Li Q Chen J Yu H Li L Wei X He HB Lu ZS Sodium intake regulates glucose homeostasis through the PPARδ/adiponectin- mediated SGLT2 pathway . Cell

Open access
Rama Lakshman Wellcome-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK

Search for other papers by Rama Lakshman in
Google Scholar
PubMed
Close
,
Charlotte Boughton Wellcome-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK
Cambridge University Hospitals NHS Foundation Trust, Wolfson Diabetes and Endocrine Clinic, Cambridge, UK

Search for other papers by Charlotte Boughton in
Google Scholar
PubMed
Close
, and
Roman Hovorka Wellcome-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK

Search for other papers by Roman Hovorka in
Google Scholar
PubMed
Close

glycaemic control and potentially reduce the need for carbohydrate counting. Sodium-glucose cotransporter-2 (SGLT2) inhibitors lower plasma glucose by blocking renal reabsorption and increasing the excretion of glucose in the urine. Their use in T1D is

Open access